Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.32 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.32 |
| ▸ | GOT1 | P17174 | 1/20 | 0.31 |
| ▸ | RXRA | P19793 | 1/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31151688 | 0.78 | — | — | |
| SCHEMBL1692004 | 0.78 | — | — | |
| Ammonia Solution, Strong SCHEMBL3579080 | 0.76 | GABRG2 (0.41) | HDAC1HDAC6HDAC5CTDSP1GOT1 | |
| SCHEMBL3476978 | 0.76 | NPC1 (0.42) | — | |
| SCHEMBL4276013 | 0.74 | NPC1 (0.39) | CTDSP1 | |
| SCHEMBL31092422 | 0.74 | — | — | |
| SCHEMBL6706994 | 0.74 | — | — | |
| SCHEMBL3076211 | 0.74 | — | — | |
| SCHEMBL23975682 | 0.73 | TSHR (0.39) | HDAC1HDAC6HDAC5CTDSP1P2RX7 | |
| SCHEMBL4272287 | 0.73 | CYP2D6 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816534-B2 | Substituted amides | MERCK SHARP & DOHME CORP. (US) | 2010-10-19 | — | — | US | disclosed |
| US-7754188-B2 | Radiolabeled cannabinoid-1 receptor modulators | MERCK SHARP & DOHME CORP. (US) | 2010-07-13 | — | — | US | disclosed |
| US-20090258884-A1 | Substituted amides | MERCK SHARP & DOHME CORP. | 2009-10-15 | — | — | US | disclosed |
| US-7576239-B2 | Substituted amides | MERCK & CO., INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-7550489-B2 | Substituted pyridyoxy amides | MERCK & CO., INC. (US) | 2009-06-23 | — | — | US | disclosed |
| EP-1575901-A4 | SUBSTITUTED AMIDES | MERCK & CO INC (US) | 2009-03-18 | — | — | EP | disclosed |
| US-20080194645-A1 | Substituted amides | MERCK SHARP & DOHME CORP. | 2008-08-14 | — | — | US | disclosed |
| US-20080171692-A1 | Substituted amides | MERCK SHARP & DOHME CORP. | 2008-07-17 | — | — | US | disclosed |
| EP-1496838-A4 | SUBSTITUTED AMIDES | MERCK & CO INC (US) | 2008-07-02 | — | — | EP | disclosed |
| US-7348456-B2 | Substituted amides | MERCK & CO., INC. (US) | 2008-03-25 | — | — | US | disclosed |
| US-20060115425-A1 | Substituted amides | MERCK SHARP & DOHME CORP. | 2006-06-01 | — | — | US | disclosed |
| US-20060106071-A1 | Substituted amides | MERCK SHARP & DOHME CORP. | 2006-05-18 | — | — | US | disclosed |
| US-6972295-B2 | Substituted amides | MERCK & CO., INC. (US) | 2005-12-06 | — | — | US | disclosed |
| US-20050234061-A1 | Substituted amides | MERCK SHARP & DOHME CORP. | 2005-10-20 | — | — | US | disclosed |
| EP-1575901-A2 | SUBSTITUTED AMIDES | Merck & Co., Inc. (a New Jersey corp.) (US) | 2005-09-21 | — | — | EP | disclosed |
| EP-1496838-A2 | SUBSTITUTED AMIDES | Merck & Co., Inc. (US) | 2005-01-19 | — | — | EP | disclosed |
| WO-2004058145-A2 | SUBSTITUTED AMIDES | MERCK & CO., INC. (US) | 2004-07-15 | — | — | WO | disclosed |
| US-20040058820-A1 | Central nervous system disorders; psychological disorders; antiinflammatory agents; multiple sclerosis | MERCK SHARP & DOHME LLC | 2004-03-25 | — | — | US | disclosed |
| WO-2003077847-A2 | SUBSTITUTED AMIDES | MERCK & CO., INC. (US) | 2003-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171692-A1 | Substituted amides | CNR1, CNR2, FAAH | HDAC1 1457/4885HDAC6 1260/4885HDAC5 1897/4885 |
| US-20060106071-A1 | Substituted amides | CNR1, CNR2, FAAH | HDAC1 1457/4885HDAC6 1260/4885HDAC5 1897/4885 |
| US-20080194645-A1 | Substituted amides | CNR1, CNR2, FAAH | HDAC1 1457/4885HDAC6 1260/4885HDAC5 1897/4885 |
| US-20040058820-A1 | Central nervous system disorders; psychological disorders; antiinflammatory agents; multiple sclerosis | CNR1, CNR2, MAG | HDAC1 2169/4885HDAC6 1457/4885HDAC5 2401/4885 |
| US-20060115425-A1 | Substituted amides | CNR1, CNR2, FAAH | HDAC1 1729/4885HDAC6 2969/4885HDAC5 2478/4885 |
| US-20090258884-A1 | Substituted amides | CNR1, CNR2, FAAH | HDAC1 1457/4885HDAC6 1260/4885HDAC5 1897/4885 |
| US-20050234061-A1 | Substituted amides | CNR1, CNR2, FAAH | HDAC1 1457/4885HDAC6 1260/4885HDAC5 1897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.